7 news items
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
for the treatment of Alzheimer's disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer's disease progression. By inducing plaque clearance
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
. In response to this challenge, the three companies have been engaged in discussions to establish a joint venture company that will seamlessly cover the entire
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
formulation of ENTYVIO as maintenance therapy in adult patients with moderately to severely active CD who had clinical response** at Week 6
Takeda Announces U.S. FDA Approval Of Supplemental New Drug Application For ICLUSIG In Adult Patients With Newly Diagnosed Ph+ ALL
TAK
19 Mar 24
that reflects deep molecular and clinical responses and is an important prognostic indicator for long-term outcomes for patients with Ph+ ALL. ICLUSIG
jazo2rx31my4awo6g8zk0delslowcmujpm9jl6fi
TAK
13 Mar 24
demonstrated a higher platelet response rate than placebo. The increases in platelet count were dose-dependent with the greatest platelet response
gwl 1h4ekkxxzsezj3bh9hpf
TAK
26 Feb 24
), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important
- Prev
- 1
- Next